跳转至内容
Merck
CN

1200000

USP

地高辛

United States Pharmacopeia (USP) Reference Standard

别名:

异羟基洋地黄毒苷

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C41H64O14
化学文摘社编号:
分子量:
780.94
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
EC Number:
244-068-1
Beilstein/REAXYS Number:
77011
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

地高辛, United States Pharmacopeia (USP) Reference Standard

InChI

1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1

InChI key

LTMHDMANZUZIPE-PUGKRICDSA-N

SMILES string

C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@H]3[C@@H](O)C[C@@H](O[C@@H]3C)O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4

grade

pharmaceutical primary standard

API family

digoxin

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

正在寻找类似产品? 访问 产品对比指南

Analysis Note

这些产品仅供测试和化验使用。它们不适用于人类或动物,也不能用于诊断、治疗或治愈任何类型的疾病。

Application

地高辛USP参标准品,预期用途是USP规定的指定质量测试和检测。也用于USP各论,例如:
  • 地高辛片
  • 地高辛注射液
  • 地高辛口服液

Biochem/physiol Actions

一种强心苷,P-糖蛋白 (Pgp) 的底物。
一种强心苷,P-糖蛋白的底物,上调 Pgp 表达和下调 SXR(固醇类异生物受体)。

General description

本产品按照发行药典的发行和规定提供。支持本产品的所有信息,包括安全数据表和任何产品信息传单,都是在发行药典的授权下开发和发布的。如需进一步信息和支持,请访问现行药典网站。

Other Notes

可能适用相应的销售限制。

pictograms

Skull and crossbonesHealth hazard

signalword

Danger

Hazard Classifications

Acute Tox. 2 Oral - Acute Tox. 3 Inhalation - STOT RE 2

存储类别

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

法规信息

危险化学品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Robert J DiDomenico et al.
Pharmacotherapy, 34(11), 1121-1131 (2014-08-29)
To compare the frequency of achieving a therapeutic serum digoxin concentration (SDC), defined as 0.5-0.9 ng/ml, by using a simplified nomogram to individualize digoxin dosing with standard dosing practices in patients with heart failure, and to characterize the relationship between
Roger W Jelliffe
Therapeutic drug monitoring, 34(4), 368-377 (2012-06-28)
Population pharmacokinetic and dynamic modeling is often employed to analyze data of steady-state trough serum digoxin concentrations in the course of what is frequently regarded as routine therapeutic drug monitoring (TDM). Such a monitoring protocol is extremely uninformative. It permits
Chang Gong et al.
Cancer research, 74(16), 4341-4352 (2014-07-02)
Phyllodes tumors of breast, even histologically diagnosed as benign, can recur locally and have metastatic potential. Histologic markers only have limited value in predicting the clinical behavior of phyllodes tumors. It remains unknown what drives the malignant progression of phyllodes
Andrew P Ambrosy et al.
Journal of the American College of Cardiology, 63(18), 1823-1832 (2014-03-13)
Digoxin is the oldest cardiac drug still in contemporary use, yet its role in the management of patients with heart failure (HF) remains controversial. A purified cardiac glycoside derived from the foxglove plant, digoxin increases ejection fraction, augments cardiac output
Laura Asnaghi et al.
PloS one, 9(8), e105372-e105372 (2014-08-29)
The transcriptional response promoted by hypoxia-inducible factors has been associated with metastatic spread of uveal melanoma. We found expression of hypoxia-inducible factor 1α (HIF-1α) protein in well-vascularized tumor regions as well as in four cell lines grown in normoxia, thus

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持